Increased metabolism in a number of cellular pathways is a common feature of malignant tumors. This metabolic hallmark of neoplastic tissue led to the development of radiopharmaceuticals for the assessment of transport and enzymatic activity for tumor diagnosis and staging. The malignant transformation causes the activation of oncogenic proteins and signaling pathways that stimulate glycolysis. The resulting high-glucose metabolism of cancer cells allows PET imaging using FDG. Other molecules frequently applied in preclinical and clinical studies are 11 C-methionine, tyrosine analogs and choline-based tracers. Using quantitative procedures they enable therapy monitoring by assessment of changes in transport and metabolization. As apoptosis is an important mechanism of cell death in tumors responding to treatment, non-invasive assessment of apoptosis using tracers for detection of phosphatidyl-serine presentation and/or caspase activation could be used as a surrogate marker for therapeutic efficacy.
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Principles of metabolism and apoptosis imaging
For visualization and/or assessment of biochemical changes in tumors, procedures are needed that (1) result in a high contrast between malignant and non-malignant tissues, or between responding and non-responding lesions during therapy, and (2) deliver quantitative data about a specific disease-associated process. As there is no 'all or nothing' difference between tumor and normal tissue, differences in quantity or quality may be important, such as an increase in expression or activity, or a shift to different protein isoforms. Usually imaging is based on a substantially higher activity and/or expression of tumors as compared with normal tissue. The underlying processes are transport of substrates, enzymatic activity, a combination of both or binding to membrane-associated structures (Figure 1 ). Examples are amino acids (transport), caspase inhibitors or substrates (enzymatic activity), fluorodeoxyglucose and fluoroethyl-choline (transport and enzymatic activity), and Annexin-V (binding to membrane structures). For measurement of enzymatic activity, substrates are preferred to inhibitors because of signal amplification, which can be obtained using the former. Signal amplification means that an enzyme converts many substrate molecules producing to multiple metabolites. This is not the case for an inhibitor, where one inhibitor molecule binds irreversibly to one enzyme molecule. It has to be stressed that nuclear medicine methods measure a radioactive signal and do not discriminate different metabolites. As metabolites may occur, tracers are preferred with one or two steps of metabolization. In combination with dynamic studies allowing the generation of time-activity curves and the use of mathematical models, pharmacokinetic modeling can be applied for the assessment of kinetic constants, which describe the biochemistry of malignant tissues in more detail. Therefore, signals obtained after administration of fluorodeoxyglucose may be further analyzed for transport as well as for phosphorylation. In a similar manner, molecules binding to plasma membrane structures may be described by kinetic constants for binding and internalization.
Imaging glucose metabolism
Malignant tumors show increased glycolytic activity, which is associated to changes in the expression of glycolysis-associated genes occurring during malignant transformation (Flier et al., 1987; Shawver et al., 1987) . Especially the gene encoding the glucose transporter subtype-1 (GLUT1) is activated early after transformation of cells with oncogenes such as src, ras or fps. An increase in the mRNA of GLUT1 is observed as early as 4-6 h after induction of the p21 c-H-ras oncoprotein, whereas changes in cell morphology occur after 72-76 h. Furthermore, the increase in GLUT1 mRNA after ras transfection was independent of the growth rate. In vivo overexpression of GLUT1 and GLUT3 was found in a series of different human and experimental tumors. The increase in GLUT1 transcription can be used for imaging or therapy by cloning of a reporter gene or a therapeutic gene, such as suicide genes downstream from the GLUT1 promoter/enhancer elements (Sieger et al., 2004; Haberkorn et al., 2005) . Examples are the Herpes Simplex Virus thymidine kinase gene or the sodium iodide symporter gene, where adeno-associated virus or retroviral vectors have been used to transfect tumor cells and measure the uptake of specific substrates, or to treat animals with genetically modified tumors (Sieger et al., 2003 (Sieger et al., , 2004 . In these studies reporter gene expression (green fluorescent protein, HSVtk or sodium iodide symporter) was specific for tumor cells or spontaneously immortalized human keratinocytes (HaCaT) with expression of an activated ras oncogene.
Besides increased glucose transport, the malignant transformation goes along with changes in the activity of glycolytic enzymes. For imaging, hexokinase is the most important enzyme. Here, a change in the isoform pattern occurs as well, with a predominant expression of hexokinase-II in all tumors, except for brain tumors where hexokinase-I may be overexpressed. In rapidly growing tumor cells, hexokinase activity is greatly enhanced, and up to 80% of the enzyme molecules are bound to the outer mitochondrial membrane, which ensures privileged access to the mitochondrial ATP pool.
These changes in transport and phosphorylation are exploited for tumor imaging by positron emission tomography (PET) using F-FDG for PET studies of glucose metabolism was introduced as a consequence of autoradiographic and biochemical studies of glucose analogs in different tissues. Similar to glucose, 2-deoxyglucose (dGlc) and fluorodeoxyglucose (FDG) are transported bi-directionally and are phosphorylated by the enzyme hexokinase. This is possible because the C-2 position unlike the C-1, C-3 and C-6 positions is uncritical for binding to the enzyme hexokinase (Gallagher et al., 1977) . In contrast to glucose-6-phosphate, FDG-6-phosphate and dGlc-6-phosphate are not further metabolized in significant amounts during PET study. dGlc-6-phosphate is not metabolized to the fructose-6-phosphate derivative and, therefore, is not a substrate for glucose-6-phosphate dehydrogenase (Sols and Crane, 1954) . dGlc-6-phosphate may be converted to dGlc-1-phosphate and uridine-diphosphate-dGlc, followed by incorporation into glycogen, glycolipids and glycoproteins. However, these reactions are very slow in mammalian tissues. Furthermore, in the brain, the organ where the deoxyglucose method was applied for the first time, as well as in malignant tumors glucose-6-phosphatase activity is downregulated. In contrast to auto-inhibition of glucose phosphorylation, FDG-6-phosphate does not show inhibition of hexokinase activity (Machado de Domenech and Sols, 1980) . Compared with 2-deoxyglucose FDG is incorporated very slowly into macromolecules as has been shown in yeasts as well as in chick fibroblasts. The negative charge on FDG-6-phosphate and dGlc-6-phosphate prevents penetration of the negatively charged inner surface of the plasma membrane and causes their accumulation in cells. A further advantage is the rapid clearance of the tracer: similar to glucose FDG shows glomerular filtration. However, unlike glucose this is not followed by tubular re-absorption, because FDG is not a substrate for the tubular sodium glucose symporter, which transports normal glucose back to he blood. This fact is responsible for the rapid renal clearance of the tracer.
PET studies in different animal models showed a correlation between FDG uptake and content of GLUT1 and hexokinase mRNA (Haberkorn et al., 1994) . Differences in FDG uptake in different lung carcinomas, with lower values for adenocarcinomas as compared with squamous cell carcinomas, corresponded to the histologically determined expression of GLUT1, which was higher in squamous cell carcinomas than in adenocarcinomas (Brown et al., 1999) . Therefore, the genetic program in malignant tumors leads to the corresponding FDG uptake values as measured by PET. Similar results were obtained in bronchioalveolar adenocarcinomas, with significantly lower values for number of GLUT1-positive cells and FDG uptake, and a correlation between histological grade and amount of GLUT1-positive cells and FDG uptake.
Originally, clinical application of 18 F-FDG predominantly focused on tumor diagnosis and in the staging of a variety of tumor entities such as lung; colon; breast; head and neck, and esophageal cancer; melanoma and lymphoma. Besides staging, the prognostic value of 18 F-FDG-PET has also been evaluated. The relation of high pre-therapeutic FDG uptake to a decrease in prognosis was observed by different groups in patients with lung cancer (Vansteenkiste et al., 1999) .
PET using 18 F-FDG has been used for the evaluation of treatment response during chemotherapy (Figure 2) , gene therapy and radiotherapy in a variety of tumors, indicating that FDG delivers useful parameters for the (1) 18 F-FDG is taken up into cells by glucose transporters and subsequently trapped after enzymatic phosphorylation by hexokinase; (2) radioactive isotopes of iodide are taken up by the human sodium iodide symporter on thyroid cancer tissues; (3) the amino acid early assessment of therapeutic efficacy (Rozental et al., 1989; Haberkorn et al., 1991 Haberkorn et al., , 1992 Haberkorn et al., , 1993 Haberkorn et al., , 1997b Haberkorn et al., , 1998 Bassa et al., 1996) . The idea is mainly that a decrease in FDG uptake in the tumor reflects a decrease in viable cell number. However, tumors may show inflammatory responses at some time period after therapeutic interventions such as radiation therapy, or stress reactions, both leading to a transient increase in glucose metabolism, especially during the very early phase during or after treatment.
In general, increased FDG transport rates, which may occur early after treatment, are suggested as evidence of stress reactions in tumors after chemotherapy, gene therapy or radiation therapy (Haberkorn et al., 1998 (Haberkorn et al., , 2001a . The glucose carrier shows a complex regulation: Glucose transport may be altered by phosphorylation of the transport protein (Hayes et al., 1993) , decreased degradation (Shawver et al., 1987) , translocation from intracellular pools to the plasma membrane (Widnell et al., 1990) or increased expression of the gene (Flier et al., 1987) . Increase in glucose transport after exposure of cells to damaging agents has been ascribed mainly to a redistribution of the glucose transport protein from intracellular pools to the plasma membrane. Such reactions have been found in cells exposed to arsenite, the calcium ionophore A23187 or 2-mercaptoethanol (Hughes et al., 1989; Widnell et al., 1990; Wertheimer et al., 1991) . Furthermore, increased glucose metabolism has been observed after chemotherapy or gene therapy of hepatoma using HSV thymidine kinase (Haberkorn et al., 1998 (Haberkorn et al., , 2001a . Incubation with deoxyglucose or the glucose transport inhibitor cytochalasin-B after the end of treatment increased the amount of apoptotic cells (Haberkorn et al., 2001a, b) , whereas monotherapy with these drugs had no effect. Enhanced glycolysis may be used for a metabolic design of combination therapy as has been done for chemotherapy (Haberkorn et al., 1992) or radiotherapy (Singh et al., 2005) . These strategies intend to disturb possible repair processes, which are in need of energy, by interfering with glycolysis. Besides deoxyglucose, a couple of compounds are available such as 6-aminonicotinamide, 3-bromopyruvate, oxythiamine, 5-thioglucose or genistein, where at least deoxyglucose shows rather selective toxicity for cells showing chemotherapy resistance (Haberkorn et al., 1992) . The design of such a combination treatment requires data about the changes in the metabolic pathways with respect to dose and time dependence, which may be obtained by 18 
F-FDG-PET.

Imaging amino-acid transport
Although PET using 18 F-FDG has been proven to be useful for diagnosis and therapy monitoring in a large variety of tumors, there is need for complementary information of tumor biology. FDG is not tumorselective and also shows accumulation in inflammatory lesions. Furthermore, tissues with a high FDG uptake background such as the brain may cause difficulties in image interpretation. Further problems arise for slowgrowing tumors or differentiated tumors such as prostate cancer or neuroendocrine tumors.
In addition to enhanced glucose metabolism, malignant tumors may show changes in amino-acid Radiolabeled amino acids may be used to assess the rate of protein synthesis and amino-acid transport. However, besides protein synthesis, amino acids are precursors for many other biomolecules, such as adenine, cytosine, histamine, thyroxine, epinephrine, melanin and serotonin, and are important in other metabolic cycles, including transamination and transmethylation; methionine has a specific role in the initiation of protein synthesis and amino acids such as glutamine are used for production of energy. As all these pathways create a dependence on amino-acid uptake, it is evident that the values obtained by measurement of amino-acid transport do not faithfully represent protein synthesis alone. Rather they provide a general measure of the cellular need for amino acids.
Amino acids enter cells mainly through specific transport systems (Christensen, 1990; Ganapathy et al., 2009) . These systems can be sodium-dependent or -independent. Sodium-dependent transport relies on the sodium chemical gradient and the electric potential across the plasma membrane, as well as on the activity of the Na þ /K þ -ATPase. In general, a change in affinity occurs when a sodium ion binds to the transporter protein. Subsequent binding of an amino acid results in a conformational change of the transporter protein, which in turn leads to an influx of the attached sodium ion and the amino acid into the cell. Sodium-independent systems depend on the amino-acid concentration gradient across the cell membrane and are often coupled to counter-transport (that is, in the opposite direction) of K þ . Kinetic studies have identified several sodium-dependent transport systems, A, ASC and Gly that transport amino acids with short polar or linear side chains, for example, alanine, serine and glycine. System-A is transinhibited by intracellular substrates (that is, the presence of intracellular substrates slows the uptake of amino acids), whereas system-ASC is trans-stimulated by the presence of intracellular substrates (that is, the presence of intracellular substrates increases activity).
The sodium-independent systems, L (ubiquitously found), B 0, þ (SLC6A14) and y þ , are carriers for branched-chain and aromatic amino acids, for example, leucine, valine, tyrosine and phenylalanine. System-L (LAT1/4F2hc) shows trans-stimulation by intracellular substrates such as leucine, valine etc. Most amino-acid carrier systems can also transport synthetic, non-metabolizable amino-acid analogs.
Regulation of amino-acid transport is complex and is influenced by hormones, cytokines, changes in cell volume and the availability of nutrients (Christensen, 1990) . For example, the number of system-A active carriers increases during starvation; hence imaging studies should be performed preferentially while patients are fasting.
Malignant cells were found to have increased aminoacid transport (Busch et al., 1959; Isselbacher, 1972; Saier et al., 1988) . Strong expression of system-A has been found in transformed and malignant cells as a result of oncogene action (Saier et al., 1988) , and in clinical studies a correlation between amino-acid transport and cellular proliferation has been described Jager et al., 2001) . The system ASCT2 (SLC1A5), which accepts neutral amino acids and prefers glutamine as substrate, has been shown to be upregulated in several types of tumors and cell lines of colorectal carcinoma and prostate carcinoma. LAT1/ 4F2hc is upregulated in brain, colon, lung, liver and skin tumors. Its expression seems to correlate with cell proliferation and cancer growth. This transporter also mediates the influx of melphalan. Finally, the xCT transporter (SLC3A2) has been found to be increased in gliomas and lymphoma cells.
For assessment of protein synthesis rate, relatively complex kinetic models are necessary. Although C-leucine appears to be the best amino acid for measuring the rate of protein synthesis (Vaalburg et al., 1992) , most studies have used methionine because of the ease of tracer synthesis. The drawbacks of methionine are its use in metabolic cycles other than protein synthesis, which results in a variety of metabolites and difficulties in quantification (Ishiwata et al., 1996) . Conflicting reports have been published about the specificity of carrier-mediated transport of methionine into brain tumors in studies comparing D-and L-methionine using an overload of branched amino acids. Furthermore, at least part of the tracer uptake seems to be a result of passive diffusion. Cellular uptake in vitro is mainly accomplished through the L-system, with minor contributions from systems A and ASC.
Patient studies have shown high uptake of methionine in the pituitary gland and pancreas, moderate uptake in salivary glands, lacrimal glands and bone marrow, and low uptake in the normal brain (Jager et al., 2001) . The tracer has been used mainly in brain tumors, where it shows excellent contrast between normal brain and tumors, and has high sensitivity for tumor detection (Langen et al., 1997) , but also for the diagnosis and staging of a variety of other tumor entities such as head and neck cancer, lung cancer, breast cancer, sarcoma and lymphoma.
An alternative to A high sensitivity for the detection of primary and metastatic brain tumors was found using either 11 C-tyrosine or L-2-18 F-fluoro-tyrosine (Wienhard et al., 1991; Willemsen et al., 1995) . Analysis of the plasma metabolites of C-L-DOPA constituted 450% of total plasma radioactivity at 40 min after injection, making a complex pharmakokinetic model for further analysis necessary. Using a five-compartment model, it was shown that, whereas the net protein synthesis rate was dependent on the recycling of amino acids from the protein, tracer influx into the cell was not.
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The curve-fitting results of dynamic scans were unreliable owing to the exchange of 11 C-tyrosine between plasma and erythrocytes, whereas the graphical PatlakGjedde analysis was not influenced by this. L-2-18 F-fluorotyrosine was studied in 15 patients with brain tumors and showed rapid uptake, which was mainly attributed to an increased transport rate. Also, improved localization of tumor tissue for biopsy has been described for both methionine and tyrosine.
L-FET, which is not incorporated into proteins, has been evaluated in mammary carcinoma-bearing mice and in mice transplanted with the colon carcinoma cell line SW707 Wester et al., 1999) . Results of transport inhibition experiments using specific competitive inhibitors have shown that uptake of L-FET into SW707 cells is caused mainly by system-L. In vivo studies showed a plasma half-life of 94 min for L-FET and increasing brain uptake up to 120 min with a brain:blood ratio of 0.9. Xenotransplanted tumors have shown a higher uptake of L-FET (46% injected dose/g) than all other organs, except the pancreas. Highperformance liquid chromatography analysis of brain, pancreas and tumor homogenates, as well as plasma samples of mice at 10, 40 or 60 min after injection, showed only unchanged L-FET, indicating high stability and lack of metabolization of the tracer. The tracer has mainly been applied in brain tumors for planning of radiation therapy, detection of tumor recurrence after therapy (Figure 4) and differentiation between inflammation and tumor (Po¨pperl et al., 2004; Pauleit et al., 2005; Salber et al., 2007; Vees et al., 2009) .
A variety of synthetic amino acids, including a-aminoisobutyric acid (AIB), 1-aminocyclopentane carboxylic (ACPC) acid, 2-amino-3-fluoro-2-methylpropanoic acid (FAMP), 3-fluoro-2-methyl-2-(methylamino)propanoic acid (N-MeFAMP) and 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC), have been synthesized and evaluated, mostly in cell culture and animal systems. AIB is thought to be actively accumulated in viable cells primarily by the A-type amino-acid transport system and has shown avid uptake in a melanoma model. Additionally, ACPC and AIB imaging was found to be 
superior to FDG in C6 gliomas and Walker 256 rat carcinosarcoma, especially for identifying tumor infiltration of adjacent brain tissue beyond the macroscopic border of the tumor, and in low-grade tumors with an intact bloodÀbrain barrier. The contrast-enhancing regions of the tumors were visualized more clearly with AIB than with FDG; viable and necrotic-appearing tumor regions could be distinguished more readily with AIB than with FDG (Uehara et al., 1997). As for AIB, amino-acid transport assays using 9L gliosarcoma cells showed that FAMP and N-MeFAMP are substrates for the A-type amino-acid transport system and show very high tumor:normal brain ratios of 36:1 and 104:1, respectively (McConathy et al., 2002) . In a rat brain tumor model, maximum tumor uptake of 18 F-FACBC was seen at 60 min, with a tumor:normal brain ratio of 5.6 at 5 min and 6.6 at 60 min after tracer administration (Shoup et al., 1999) .
Measurement of the effects of therapy on tumor metabolism may be useful in predicting therapy outcome at an early stage of treatment. This principle may be applied not only to glucose metabolism but also to amino-acid transport and metabolism. Studies of various human tumors treated with a variety of therapies and of the rat AH109A tumor model after radiotherapy showed a rapid post-therapeutic reduction in methionine uptake, reflecting inactivation of protein synthesis and damage to the membrane transport system (Bergstrom et al., 1987; Jansson et al., 1995; Schaider et al., 1996) . Furthermore, uptake of L-1-11 C-tyrosine in the rhabdomyosarcoma of Wag/Rij rats was dose dependently reduced after local hyperthermia (Daemen et al., 1991) . Moreover, accumulation of AIB is decreased in rat prostate tumors after long-term treatment with stilbestrol (Dunzendorfer et al., 1981) . These changes were followed later by a reduction in tumor mass.
In vitro studies have shown that methotrexate and cisplatin induce a decline in AIB and methionine accumulation in L1210 murine leukemia cells (Scanlon et al., 1983 (Scanlon et al., , 1987 , leading to the speculation that inhibition of methionine uptake by methotrexate may be because of the drug binding to a specific membrane carrier, or reduction in the sodium gradient across the plasma membrane, which is necessary for uptake of amino acids, or effects on intracellular processes, which support the uptake of amino acids. Higashi et al. (1993) showed an increase in methionine and FDG uptake in human ovarian carcinoma cells after radiotherapy, which was accompanied by an increase in cell volume. These phenomena were interpreted as giant cell formation with enlarged cellular volume and continued protein synthesis, but accelerated repair was also suggested. Another in vitro study combined information obtained from experiments using a transport tracer (AIB) and a tracer, which is transported and metabolized (methionine), and found a decrease in neutral amino-acid transport after gene therapy of hepatoma cells using HSV thymidine kinase and ganciclovir, indicating treatment effects on the energy-dependent transport systems (Haberkorn et al., 1997a) . Methionine uptake experiments showed a decrease in tracer accumulation in the acid-insoluble fraction (representing nucleic acids and proteins), indicating impaired protein synthesis and an increase in the acid-soluble fraction. The increase of radioactivity found in the acid-soluble fraction may be caused by enhanced transmethylation processes, which usually are observed during oncogenic transformation and after exposure to DNA-damaging agents.
Clinical studies in brain tumors have been conducted for early evaluation of treatment response and differentiation between recurrence and radiation necrosis. In 10 patients with low-grade gliomas, a dose-dependent reduction in methionine uptake was seen after brachytherapy (Wurker et al., 1996) . Differentiation between radiation necrosis and tumor recurrence was possible by methionine-PET (Ogawa et al., 1991) . After radiotherapy of head and neck cancer, a lower posttherapeutic methionine uptake was shown to correlate with therapy response (Lindholm et al., 1998) . Similar results were obtained in patients after radiotherapy or chemotherapy of lung, breast and rectal cancer (Daemen et al., 1991; Jansson et al., 1995) . However, the predictive value of methionine-PET remains questionable.
Amino acids have been suggested to be useful for differentiation between inflammation and malignancy. Experimental studies have shown that amino acids accumulate less in inflamed tissue than FDG. However, amino-acid uptake may occur in benign lesions such as ischemic brain, infarction, scar, abscesses and sarcoidosis, and also in irradiated areas. Therefore, active inflammatory cells may need amino acids, and the specificity of amino acids for tumor imaging is not absolute. However, in mice with tumor-infiltrated or inflammatory lymph nodes, accumulation of L-FET showed significant differences, with no overlap between inflammatory and tumorous nodes (Rau et al., 2002) .
In summary, amino acids may have a potential role in the characterization of the biological properties of tumors as increased amino-acid transport or protein synthesis. Advantages over FDG imaging can be expected in the imaging of brain tumors, because the background of tracer accumulation is lower as compared with FDG. The role of amino acids for monitoring the treatment response of tumors as well as the differentiation between inflammation and tumor tissue has to be established in further studies.
Imaging of choline phospholipid metabolism
Elevated levels of phosphocholine, phosphoethanolamine and total choline have been detected by in vivo and in vitro 1 H and 31 PMR spectroscopic studies in a variety of tumors, including breast, prostate and brain tumors (Negendank, 1992; de Certaines et al., 1993; Leach et al., 1998) . Phosphocholine is a precursor as well as a breakdown product of phosphatidylcholine, the most abundant phospholipid found in biological membranes. The molecule together with other phospholipids such as phosphatidylethanolamine is involved in the formation of the bilayer structure of the cell membrane and regulates membrane integrity (Ackerstaff et al., 2003) . In addition, synthesis and hydrolysis of phosphatidylcholine are essential for mitogenic signal transduction (Cai et al., 1993) . In that respect, the products of choline phospholipid metabolism, such as phosphocholine and diacylglycerol, may function as second messengers for the mitogenic activity in the activation of the ras-raf-1-mitogen-activated protein kinase (MAPK) cascade and the protein kinase-C pathway (Cai et al., 1993) . A couple of studies showed that activation of choline uptake and phosphorylation is rather a late event involved in a cascade of intracellular signal transduction events that results in cellular transformation. This was seen for activation of the ras-GTPaseactivating protein, the phosphatidylinositol-3-kinase and other tyrosine kinases (Molloy et al., 1989; Kypta et al., 1990; Cuadrado et al., 1994; Galetic et al., 1999) . In quiescent NIH3T3 fibroblasts, DNA synthesis was stimulated by phosphocholine, with no effect for choline, phosphorylserine and phosphoethanolamine. Furthermore, incubation with the choline kinase inhibitor HC-3 blocked growth factor induced proliferation, an effect that could be reversed by addition of phosphocholine. Therefore, phosphocholine is seen as an important second messenger for mitogenic activity, with choline kinase activity as a critical step for the regulation of cell proliferation (Cuadrado et al., 1993) .
Besides growth factors, choline phospholipid metabolism is regulated through a variety of mechanisms, including stimulation by cytokines (Bogin et al., 1998), oncogenes (Aboagye and Bhujwalla, 1999; Ronen et al., 2001) , hypoxia and chemical carcinogens (Kiss et al., 1993; Galons et al., 1995) .
The mechanisms responsible for the increased phosphocholine levels in malignant cells are an increase in the expression and activity of choline kinase (Ramirez de Molina et al., 2002a, b) , choline transport activity (Haeffner, 1975; Katz-Brull and Degani, 1996) and elevated levels of enzyme activity for phospholipase-D (Noh et al., 2000) and phospholipase-A2 (Guthridge et al., 1994) . Choline kinase is the first enzyme involved in the Kennedy pathway and transforms choline into phosphocholine. Its enzyme activity is upregulated by growth factors, chemical carcinogens and oncogenes (Hernandez-Alcoceba et al., 1999) . Incubation of Ehrlich ascites tumor cells with 3 H-or 14 C-choline showed that choline was taken up at low concentrations by an active transport mechanism and converted into phosphorylcholine within 1 h, followed by degradation to phosphatidylcholine (Haeffner, 1975) .
The mentioned changes in choline content and metabolism have been used for tumor diagnosis by proton magnetic resonance spectroscopy, which is usually performed in combination with anatomical MRI. Pre-and post-therapy studies showed that combined MRI and magnetic resonance spectroscopic imaging was able to assess the presence and localization of cancer, as well as the effects of treatment (Leach et al., 1998; Kurhanewicz et al., 2000) . This has been done for a variety of tumors, including prostate, brain and breast cancer (Negendank, 1992; Gribbestad et al., 1999; Kurhanewicz et al., 2000; Li et al., 2002) .
Furthermore, radiolabeled choline analogs have been used for tumor detection by PET in many tumor entities such as brain tumors, lung cancer, esophageal cancer, colon cancer, bladder cancer and prostate cancer (Hara et al., 1998 (Hara et al., , 2002 Kobori et al., 1999; DeGrado et al., 2000 DeGrado et al., , 2001 Kwee et al., 2004 Kwee et al., , 2006 . As mentioned above, choline is transported into cells. Thereafter, it is rapidly metabolized to phosphocholine or oxidized by choline dehydrogenase and betainealdehyde dehydrogenase to betaine. The latter occurs mainly in the liver and kidneys. Phosphorylation of choline by choline kinase represents the first and obligatory step for the incorporation of choline into phosphatidylcholine. The resulting first metabolite, phosphocholine, is negatively charged and, therefore, trapped within the cell.
Several choline-based tracers exist that have been synthesized and evaluated pre-clinically as well as in patients, for example, 11 C-choline, 18 F-fluoro-choline and 18 F-fluoroethyl-choline ( Figure 5 ). Comparative studies in vitro showed that fluoro-choline uptake in PC-3 prostate cancer cells was similar to choline uptake. Furthermore, a 90% decrease of tracer uptake was seen after pretreatment with HC-3, a specific inhibitor of choline uptake and phosphorylation (DeGrado et al., 2000, 2001) . Experiments in tumor bearing mice showed a similar bio-distribution as with 11 C-labeled choline. At 1 h after administration the tumor:blood ratio was 5:1, suggesting trapping of tracer in the tumor cells, consistent with phosphorylation by choline kinase activity.
The blood clearance of 18 F-fluoro-choline was very rapid in patients, leading to an excellent contrast between tumor and background in PET images at 3 min after tracer administration. In comparison with 11 C-choline, 18 F-fluoro-choline and 18 F-fluoroethyl-choline showed a higher renal clearance. It is known that choline is efficiently reabsorbed by the renal proximal tubular cells. Thus, the main route of clearance relies on the oxidation of the molecule by the enzymes choline dehydrogenase and betaine-aldehyde dehydrogenase, which convert choline into betaine. Thereafter, betaine is excreted in the urine. Therefore, it is likely that the very rapid appearance of fluorinated choline tracers is because of incomplete tubular re-absorption of the intact tracer or owing to enhanced excretion of oxidative metabolites (DeGrado et al., 2000 (DeGrado et al., , 2001 . In benign prostate tissues, a decrease of tracer accumulation was observed with time, also leading to a higher contrast between tumor and normal tissue. It has been suggested that this is because of dephosphorylation of 18 F-phosphorylfluoro-choline by prostatic acid phosphatase, an enzyme specific for prostate tissues (DeGrado et al., 2000 (DeGrado et al., , 2001 . Normal prostate tissue as well as prostate hyperplasia contain higher levels of prostatic acid phosphatase than prostate carcinoma, which accepts phosphocholine and possibly also 18 F-phosphorylfluoro-choline as a substrate.
Imaging apoptosis
For in vivo detection of apoptosis mainly two targets in the apoptotic pathway are of interest: (1) The presentation of phosphatidylserine residues at the outer surface of the plasma membrane and (2) the appearance of activated caspases (Martin et al., 1995; Villa et al., 1997) . Phosphatidylserine is maintained at the inner surface of the plasma membrane by the ATP-dependent enzymes floppase and translocase (Zwaal and Schroit, 1997) . Apoptosis induced inactivation of these enzymes, and activation of a scramblase leads to the appearance of phosphatidylserine on the outer surface of the membrane. This effect has been used to develop an imaging agent for apoptosis (Blankenberg et al., 1998 (Blankenberg et al., , 1999 : Annexin-V, a 35-kDa human protein with high affinity for cell membrane-bound phosphatidylserine, was labeled with 99m Tc and investigated for its uptake in apoptotic cells. An increased accumulation was found in Jurkat cells, where programmed cell death was initiated by growth factor deprivation, anti-CD95 antibody and doxorubicin treatment. Also anti-CD95-treated mice showed a threefold rise in hepatic 99m Tc-Annexin-V accumulation in response to severe liver damage, with histological evidence of apoptosis. Finally, increased uptake was detected in animal models using acute rejection of transplanted heterotopic cardiac allografts or transplanted murine B-cell lymphomas treated with cyclophosphamide (Blankenberg et al., 1999) . Figure 6 shows a patient studied with 99m Tc-Annexin-V after treatment.
As caspases have a key role during the early period of the intracellular signal cascade of cells undergoing apoptosis, benzyloxycarbonyl-Val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone (Z-VAD-fmk), a pan-caspase inhibitor, was evaluated as a potential apoptosisimaging agent (Haberkorn et al., 2001c) . Uptake measurements were performed using Morris hepatoma cells (MH3924Atk8), which showed expression of the Herpes Simplex Virus thymidine kinase (HSVtk) gene. Apoptosis was induced by treating cells with ganciclovir and a twofold increase in [ ]IZ-VAD-fmk was found to be low. Besides peptidic molecules, a couple of isatin sulfonamide analogs have been identified as potent inhibitors of executioner caspases such as caspase-3 and caspase-7 and, therefore, have been radiolabeled for use in apoptosis imaging (Zhou et al., 2009) .
As inhibitors suffer from the drawback that one inhibitor molecule binds to one enzyme molecule, the Figure 6 Transaxial SPECT/CT images of a patient with non-small-cell lung cancer after chemotherapy: CT (left), SPECT (middle) and fusion image (right). The tumor (at the center of the crosshairs) and the central lymph node metastasis show accumulation of 99m Tc-Annexin-V after chemotherapy, indicating apoptosis. Unspecific accumulation is seen in the sternum and the vertebra. CT, computed tomography.
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U Haberkorn et al signal obtained is rather weak. Instead of using an inhibitor, synthetic caspase substrates are investigated, which may accumulate in an apoptotic cell by metabolic trapping, thereby enhancing the imaging signal. In one of these studies, 10 radiolabeled peptides containing the DEVDG sequence, selective for downstream caspases such as caspase-3, were synthesized and evaluated for their uptake kinetics using an apoptosis test system (Bauer et al., 2005) .Within this series of peptides, radioiodinated Tat49-57-yDEVDG-NH 2 and Tat57-49-yDEVDG-NH 2 , both containing an additional HIV Tat sequence, were taken up by apoptotic cells to a significant higher extent as compared with controls. This enhanced uptake was interpreted as interaction of the labeled peptide or fragment with activated caspases. Current efforts are focused on alternative radioisotopes, including radiometal complexes, to further improve these characteristics. In summary, all these imaging procedures may be used to characterize the biological features of tumors and their metastases with respect to metabolism, apoptosis and microenvironment. The information obtained with these techniques can be expected to individualize treatment, and makes radioisotope-based methods promising tools for tumor detection, therapy planning and therapy monitoring.
